Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life >10 hours, robust…
Company’s award winning SSi Mantra surgical robotic system has completed over 550 surgeries and is clinically validated to perform more…
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety…
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer…
Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024…
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader…
iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase…
Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount…
LONDON, UK / ACCESSWIRE / January 8, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), which is developing new therapies and treatments…
Live the Way is Pioneering An Evidence-Based Approach to Health and Well-BeingLAS VEGAS, NV / ACCESSWIRE / January 5, 2024…